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PROTECTION AGAINST ISCHEMIA AND 
REPERFUSION INJURY 
This application claims the bene?t of US. Application 
Ser. No. 60/238,989, ?led on Oct. 10, 2000. 
FIELD OF THE INVENTION 
The invention relates to compounds protective against 
ischemia and reperfusion injury, particularly in the 
myocardium, and their use. 
BACKGROUND 
Tissues deprived of blood and oxygen undergo ischemic 
necrosis or infarction With possible irreversible organ dam 
age. In some circumstances, hoWever, such as during cardiac 
surgery, it is desirable to interrupt the normal myocardial 
contractions (cardioplegia) and actually induce ischemia. 
Such elective or obligatory ischemia occurs in the presence 
of safeguards such as cardioplegia-induced cardiac arrest 
and hypothermia. While these safeguards provide consider 
able myocardial protection, alteration of myocardial ener 
getics (stunning) and poor postoperative ventricular function 
still remain signi?cant problems. 
Once the How of blood and oxygen is restored to the organ 
or tissue (reperfusion), the organ does not immediately 
return to the normal preischemic state. Reperfused postis 
chemic non-necrotic myocardium is poorly contractile and 
has reduced concentrations of high energy nucleotides, 
depressed subcellular organelle function and membrane 
damage that resolves only sloWly. Although reperfusion 
restores oxygen and reverses ischemia, repletion of high 
energy nucleotides such as adenosine triphosphate (ATP) 
and reversal of ischemic membrane damage is sloW, and 
contractile function may be profoundly depressed for a long 
period. Just minutes of ischemia causes loss of myocardial 
systolic Wall thickening for hours. Longer periods of revers 
ible ischemia may depress contractility for days. Studies 
con?rm that, despite restoration of myocardial How and a 
quick recovery of myocardial oxygen consumption (MVO2) 
folloWing ischemia, there is only very sloW recovery of 
myocardial contractile function. The problems are exacer 
bated in high risk patients, such as those With poor preop 
erative ventricular function, recent myocardial infarction or 
left ventricular hypertrophy. These same problems also 
occur during organ storage for cardiac transplant, under 
Which there are time constraints due to the limits of myo 
cardial preservation. 
Postischemic dysfunction may be due to a variety of 
factors. Oxygen free radicals may play a role, as generation 
of free radicals in stunned myocardium has been demon 
strated and free radical scavengers have been shoWn to 
attenuate contractile dysfunction. Impaired intracellular cal 
cium handling and calcium overload during early reperfu 
sion may contribute to postischemic dysfunction; While 
calcium infusions enhance contractility in both normal and 
postischemic myocardium, ischemia as short as a feW min 
utes produces an impairment in sarcoplasmic reticulum 
calcium transport and a shift of the calcium ATPase activity. 
Postischemic myocardium is also associated With reduced 
concentrations of myocardial high-energy phosphates and 
adenine nucleotides, as obligatory reduction in myocardial 
ATP content during ischemia occurs as myocytes utiliZe ATP 
for maintenance of cellular integrity. Since ATP is essential 
for myocardial contraction and relaxation, ATP depletion 
may have detrimental effects upon postischemic myocardial 
functional recovery. 
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The high volume of cardiac-related surgeries, both elec 
tive and emergency procedures and including cardiac 
transplants, lead to the above-described problems. Thus, 
methods and agents to provide protection against myocardial 
ischemia and to avoid post ischemic dysfunction are needed. 
SUMMARY OF THE INVENTION 
The invention is directed to an agent and a method of 
using the agent to reduce the injury associated With ischemia 
and reperfusion of organs such as the heart. The compound 
is Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp 
Phe-Phe-His-Ser-Ile-NH2 (SEQ ID NO:1), hereinafter 
referred to as compound-D. Administration of compound-D 
SEQ ID NO:1, particularly prior to an ischemic event, 
reduces tissue necrosis and preserves organ function. 
In one embodiment, a method of protecting against 
ischemia and reperfusion injury in a mammal is disclosed. 
An effective concentration of compound-D SEQ ID NO:1 is 
administered to the mammal in a pharmaceutically accept 
able formulation prior to the onset of ischemia, for example, 
24 hours prior to ischemia. In other embodiments, 
compound-D SEQ ID NO:1 is administered substantially 
concurrent With the onset of ischemia, during an ischemic 
episode, or post-ischemia. The formulation may be admin 
istered parenterally at an amount in the range of about 1—20 
mg/kg of body Weight. 
The invention is also directed to a method to prevent 
damage to an isolated organ, for example, a heart for 
transplant. The isolated organ is exposed to a preservative 
solution containing an effective amount of compound-D 
SEQ ID NO:1. The concentration of compound-D SEQ ID 
NO:1 in the preservative solution for a heart is about 100 
pM. 
The invention is additionally directed to a method for 
reducing effects of an ischemic episode in a mammal by 
administering an effective concentration of compound-D 
SEQ ID NO:1 in a pharmaceutically acceptable carrier. 
Administration is prior to or substantially concurrently With 
the onset of ischemia, or one hour post cerebral ischemia. 
The invention is further directed to a composition that 
protects a mammalian organ from injury. The composition 
contains compound-D SEQ ID NO:1. Compound-D may be 
naturally occurring or may be synthesiZed. 
The invention is also directed to an organ preservative 
solution that contains compound-D at a concentration effec 
tive to protect the organ, such as a heart, from ischemic 
injury. 
These and other advantages of the invention Will be 
apparent in light of the folloWing draWings and detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a histogram shoWing myocardial infarction siZe 
in control and treated animals. 
FIG. 2 is a histogram shoWing post-ischemic release of 
creatine kinase in control and treated animals. 
FIG. 3 is a histogram shoWing post-ischemic release of 
troponin I in control and treated animals. 
FIG. 4 is a graph shoWing end diastolic pressure in the left 
ventricle of control and treated animals. 
FIG. 5 is a graph shoWing functional recovery in control 
and treated animals. 
FIG. 6 is a graph shoWing coronary How in control and 
treated animals. 
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FIG. 7 is a histogram showing the effect of naltrexone on 
infarct siZe in animals pretreated With compound-D SEQ ID 
NO:1. 
FIG. 8 is a histogram shoWing the effect of glibenclamide 
on vas deferens contractility in animals treated With 1,000 
nM compound-D SEQ ID NO:1. 
FIG. 9 is a histogram shoWing the effect of glibenclamide 
on vas deferens contractility in animals treated With 2,000 
nM compound-D SEQ ID NO: 1. 
FIG. 10 is a histogram shoWing the effect of compound-D 
SEQ ID NO:1 on cell metabolic activity. 
FIG. 11 is a histogram shoWing the effect of compound-D 
SEQ ID NO:1 on cell viability. 
FIG. 12 is a graph shoWing cell viability and metabolic 
activity With increasing concentrations of compound-D SEQ 
ID NO:1. 
FIG. 13 is a histogram shoWing the effect of compound-D 
SEQ ID NO:1 on cells exposed to oxidative damage. 
DETAILED DESCRIPTION 
The invention is directed to a compound that has a 
salutary effect on cardiac function folloWing ischemia, and 
methods of using the compound. The compound may be 
administered directly to an individual, and is particularly 
effective When administered 24 h prior to the onset of 
ischemia. This may occur, for example, prior to scheduled 
cardiac surgery. The compound may also be included in a 
preservative solution for an isolated organ, such as a heart or 
liver being maintained viable for transplant. 
The compound is a peptide having the sequence Tyr-D 
Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe 
His-Ser-Ile-NH2 SEQ ID NO: 1, hereinafter referred to 
compound-D. The peptide may be produced by a number of 
methods, such as using an automated peptide synthesiZer, 
through recombinant molecular techniques, or isolated from 
a naturally occurring source, as is knoWn to one skilled in the 
art. Compound-D SEQ ID NO:1 has a molecular Weight of 
1,902 daltons. Compound-D SEQ ID NO:1 is insoluble in 
Water or saline, but may be solubiliZed by adding 100 pM of 
a solution comprised of ethanol, propylene glycol, and 1 N 
NaOH in a 1:111 ratio, With sterile physiological saline then 
used to obtain the appropriate concentration. The initial 
alkaline pH is adjusted to 7.4 With 1 N HCl. 
Compound-D SEQ ID NO:1 that has been solubiliZed 
may be administered by parenteral means, for example, by 
intravenous injection. In one embodiment, administration of 
compound-D SEQ ID NO:1 is at the time of induced 
ischemia, fut may also be added during or even after an 
ischemic event. For administration into a mammal, a dose of 
about 1—20 milligrams per kilogram (mg/kg) is useful. For 
administration into a tissue or organ preservation solution, a 
concentration of about 100 pM is useful. 
Compound-D SEQ ID NO:1 may be administered directly 
into a mammal, either alone or in combination With other 
substances. Alternatively, it may be added as a component of 
a solution used to maintain the viability of isolated organs, 
such as an additive to cardioplegia and other organ preser 
vation solutions. In one embodiment, compound-D SEQ ID 
NO:1 is coadministered as an adjuvant With other com 
pounds or strategies that are designed to protect organs from 
ischemia. As an example, compound-D SEQ ID NO:1 may 
be administered With agents that affect nitric oxide (NO) 
synthase, such as arginine hydrochloride. Arginine hydro 
chloride is knoWn to prevent the decline in cardiac function 
folloWing an ischemic episode. 
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The folloWing description demonstrates use and ef?cacy 
of compound-D SEQ ID NO:1 in a variety of systems. 
Perfused Heart 
Compound-D SEQ ID NO:1, at a dose of 2 mg/kg and 
solubiliZed as described above, Was administered by tail 
vein injection into rats Weighing betWeen about 350—400 g 
(number of animals (n)=6). Control rats (n=6) Were injected 
in the same manner With an equal volume of 0.9% NaCl. 
After 24 h, the hearts from both treated and control animals 
Were excised and perfused in a modi?ed Langendorff per 
fusion apparatus at 37° C. using oxygenated Krebs 
Henseleit buffer as the perfusate, as knoWn to one skilled in 
the art. Coronary perfusion pressure Was maintained at 700 
mm Hg by regulating coronary ?oW. All hearts Were paced 
at 5.5 HZ (300 beats per minute, bpm) except during 
ischemia. A saline-?lled balloon Was inserted in the left 
ventricle to measure developed pressure (DP) and end 
diastolic pressure (EDP) in mm Hg. After 15 min 
equilibration, both groups Were subjected to 20 min Zero 
?oW global ischemia, and then Were reperfused for 120 min. 
Left ventricles Were isolated and divided into three seg 
ments along their short axis, stained With triphenyltetraZo 
lium chloride, and stored in formalin. Infarct siZe Was 
measured on digitiZed images and expressed as a percentage 
of myocardium. Data Were expressed as mean plus or minus 
standard error of the mean (:SEM) and Were analyZed using 
a paired Student’s t-Test. Con?dence limits Were established 
at 95%. 
The results are shoWn in FIG. 1, Which is a histogram of 
the infarct siZe in hearts from both animals receiving only 
saline (control, solid bar) and in animals treated With 
compound-D SEQ ID NO:1 at 2.0 mg/kg (treated, open bar) 
24 h prior to 20 min ischemia and 120 min reperfusion. 
Pretreatment of animals With compound-D SEQ ID NO:1 
signi?cantly decreased the percent of infarct siZe (p<0.05). 
Control rats had a mean infarct siZe of 27:5%, While rats 
pretreated With compound-D had a reduced mean infarct 
siZe of 12:3%. 
Compound-D SEQ ID NO:1 pretreatment also signi? 
cantly decreased total creatine kinase (CK) and the cardiac 
form of troponin I (cTn-1) values folloWing 20 min 
ischemia, as shoWn in FIGS. 2 and 3,respectively. CK is an 
enZyme that is normally found in muscles such as the heart 
(that is, in myocytes), but is released during severe muscle 
trauma such as occurs in a myocardial infarction. Thus, 
measurement of CK is an indicator of the degree of muscle 
damage or trauma. Similarly, cTn-I is a protein associated 
speci?cally With cardiac muscle, and an increase in cTn-1 
indicates myocardial damage. 
FIG. 2 is a histogram shoWing CK released during rep 
erfusion of isolated rat hearts after 20 min ischemia in rats 
treated 24 h prior to ischemia With 2.0 mg/kg compound-D 
SEQ ID NO:1. The solid bars represent control animals 
(n=6) and the open bars represent treated animals (n=6). 
FIG. 3 is a histogram shoWing cTn-I released during reper 
fusion of isolated rat hearts after 20 min ischemia in rats 
treated 24 h prior to ischemia With 2.0 mg/kg compound-D 
SEQ ID NO:1. The solid bars represent control animals 
(n=6) and the open bars represent treated animals (n=6). At 
each time point during reperfusion Where samples Were 
collected for CK and cTn-1 analysis (1, 15, 30, 60, 90 and 
120 min reperfusion), CK levels in control rats Were higher 
than CK levels in treated rats, and Tn-1 levels in control rats 
Were higher than Tn-1 levels in treated rats. This indicated 
that pretreatment With compound-D SEQ ID NO:1 
decreased the damage to the myocardium, as compared to 
animals that did not receive compound-D SEQ ID NO:1. 
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Compound-D SEQ ID NO:1 pretreatment also resulted in 
improved postischemic ventricular function. FIG. 4 is a 
graph of end diastolic pressure (EDP) in mm/Hg in the left 
ventricle during reperfusion of isolated rat hearts after 20 
min ischemia in rats treated 24 h prior to ischemia With 2.0 
mg/kg compound-D SEQ ID NO:1. Open squares are from 
treated animals, and solid circles are from control animals. 
FIG. 5 is a graph shoWing percent of functional recovery 
during reperfusion of isolated rat hearts after 20 min 
ischemia in rats treated 24 h prior to ischemia With 2.0 
mg/kg compound-D SEQ ID NO:1. Open squares are from 
treated animals, and solid circles are from control animals. 
Differences in recovery of developed pressure (DP) of 
compound-D SEQ ID NO:1 treated hearts remained statis 
tically signi?cant to 90 min folloWing initiation of 
reperfusion, as shoWn in FIG. 4, and in end diastolic 
pressure to 20 min folloWing initiation of reperfusion, as 
shoWn in FIG. 5. Left ventricular functional recovery (% 
recovery of baseline preischemic developed pressure during 
reperfusion) Was markedly improved in treated animals 
(open squares) compared to control animals (solid circles) to 
90 min of reperfusion. As shoWn in FIG. 6, coronary How 
Was not signi?cantly different betWeen control animals 
(solid circles) and compound-D SEQ ID NO:1 treated 
animals (open squares). 
These results shoW that in a normoXic, isolated perfused 
rat heart preparation, administration of compound-D can 
confer cardioprotection When administered 24 h prior to 
planned ischemia. The salutary effects on the post-ischemic 
myocardium include reduced infarct siZe, decreased release 
of both creatine kinase and cardiospeci?c troponin I, and 
improved ventricular performance. 
FIG. 7 shoWs the effect of naltreXone, a universal opioid 
antagonist, on infarct siZe. Groups of rats Were pretreated 24 
h prior to ischemia With either compound-D SEQ ID NO:1 
at a dose of 2.0 mg/kg (n=6), naltreXone at a dose of 3 mg/kg 
(n=6), or a combination of compound-D SEQ ID NO:1 at a 
dose of 2.0 mg/kg and naltreXone at a dose of 3 mg/kg (n=6). 
Control rats (n=6) received vehicle (1:1:1 solution of 1N 
NaOHzpropyleneglycol:ethanol, readjusted to 7.4 With HCl) 
only. After 24 h pretreatment, isolated rat hearts Were 
subjected to 20 min ischemia folloWed by 120 min reper 
fusion. 
As shoWn in FIG. 7, these data indicate that naltreXone 
administered in combination With compound-D SEQ ID 
NO:1 did not block the cardioprotective effects of 
compound-D SEQ ID NO:1. In fact, the data support a 
synergistic cardioprotective effect from administration of a 
combination of compound-D SEQ ID NO:1 and naltreXone. 
Administration of compound-D SEQ ID NO:1 reduced 
infarct siZe from about 27% in the control group (solid bar) 
to about 13% in the compound-D SEQ ID NO:1 treated 
group (open bar) (p=0.05). The combined preischemic 
administration of compound-D SEQ ID NO:1 and naltreX 
one (doWnWard hatched bar) reduced infarct siZe to about 
10% When compared to the control group (p=0.05). 
Additionally, these data demonstrate that compound-D SEQ 
ID NO:1 does not operate via delta opioid receptors, since 
naltreXone, an opioid receptor antagonist, did not prevent 
compound-D SEQ ID NO:1 activity in reducing infarct siZe 
(about 14.5% versus about 13%, respectively). 
Mouse Vas Deferens 
Utilizing a mouse vas deferens (m.v.d.) assay, 
compound-D SEQ ID NO:1,it Was demonstrated that opioid 
receptor binding requires activation and/or opening of 
adenosine triphosphate-sensitive potassium (KATP) chan 
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nels. Glibenclamide, a KATP channel blocker, blocked the 
inhibition of contraction of mouse vas deferens induced by 
compound-D SEQ ID NO:1. With reference to FIG. 8, the 
effect of administration of 1000 nM compound-D SEQ ID 
NO:1 alone (open bar) versus 1000 nM compound-D SEQ 
ID NO:1 With 6000 nM glibenclamide (hatched bar) on 
contractility of mouse vas deferens (m.v.d.) (n=6) is shoWn. 
Glibenclamide restored m.v.d. contractions Which 
compound-D SEQ ID NO:1 had suppressed. FIG. 8 shoWs 
that 1000 nM compound-D SEQ ID NO:1 suppressed con 
tractility to above 100%. FIG. 8 also shoWs that differences 
betWeen control contractions and 1000 nM compound-D 
SEQ ID NO:1, as Well as control versus 6000 nM 
glibenclamide, and 1000 nM compound-D SEQ ID NO:1 
versus 6000 nM glibenclamide are statistically signi?cant. 
FIG. 9 shoWs the effect of administration of 2000 nM 
compound-D alone (open bars) versus 2000 nM 
compound-D SEQ ID NO:1 With 6000 nM glibenclamide 
(hatched bar) on contractility of m.v.d. (n=2). 
These results demonstrate that the effect of compound-D 
SEQ ID NO:1 requires opening and/or activation of KATP 
channels since glibenclamide, a potassium channel blocker, 
effectively blocked the smooth muscle inhibition of contrac 
tion induced by compound-D SEQ ID NO:1 in the m.v.d. 
assay. The possibility therefore eXists that administration of 
compound-D SEQ ID NO:1 and interventions directly tar 
geted at opening KATP channels by drugs such as nicorandil 
or diaZoXide, or anesthetics such as iso?urane, could be 
effective approaches for pharmacologically duplicating both 
short term and long term (second WindoW) ischemic pre 
conditioning. Thus, preinfusions of compound-D SEQ ID 
NO:1 may provide extended protection to the ischemic 
myocardium in a variety of clinical scenarios. 
Compound-D, SEQ ID NO:1 has also been shoWn to be 
effective in reducing ischemic effects When administered 1 
h after an episode of induced cerebral ischemia. A solution 
of 100 ML of either vehicle alone (control) or compound-D 
(treated) at a concentration of 1 mg/ml Was administered 
either 1 h before cerebral ischemia or 1 h after cerebral 
ischemia (n=6 in each group). In animals receiving 
compound-D before ischemia, there Were no signi?cant 
differences in infarct volume (control 91:10 mm3 versus 
treated 89:11 mm3) or neurological score (control group 
1.93:0.29 versus treated group 1.95:0.33). HoWever, When 
compound-D Was administered 1 h post ischemia, there 
Were signi?cant difference in both the infarct volume 
(control group 90:13 mm3 versus treated group 5619 mm3) 
and the neurological score (control group 1.91:0.27 versus 
treated group 1421028) in rats receiving compound-D SEQ 
ID NO:1 versus the control group. The mean arterial blood 
pressure, pO2,pCO2, pH and cerebral blood ?oW shoWed no 
signi?cant differences in control versus treated groups When 
compound-D SEQ ID NO:1 Was administered either pre- or 
post-cerebral ischemia (data not shoWn). These results sug 
gest a therapeutic role for compound-D SEQ ID NO:1 in 
mitigating the effects of a cerebral ischemic episode that is 
in progress or that has occurred. 
Cultured Cell Lines 
The rat pheochromocytoma cell line, P012 (ATOC; CRL 
1721) Was cultured in groWth medium, RPMI 1640 medium 
supplemented With 10 mM HEPES (N-2-hydroXyethyl 
piperaZine-N‘-(2‘-ethanesulfonic acid)), 1 mM sodium 
pyruvate, 2 mM L-glutamine (GIBCO BRL), 10% horse 
serum (HS; Sigma), and 5% fetal bovine serum (FBS; JRH). 
Ten to tWelve days prior to assay, PC12 cells Were induced 
With 50 ng/ml recombinant human beta nerve groWth factor 
(NGF; R&D Systems) to the neuronal phenotype on col 
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lagen I coated tissue culture dishes. TWo days prior to assay, 
cells Were plated on collagen IV coated 48-well tissue 
culture plates Without NGF at 3—5><105 cells per Well. 
For hypoxic/ischemic conditions, the medium Was 
changed to either Dulbecco’s Modi?ed Eagle Medium 
(DMEM; GIBCO BRL) Without glucose, or DMEM With 5 
mM glucose. Both Were supplemented With 10 mM HEPES 
containing compound-D SEQ ID NO:1 at various concen 
trations. Cells Were placed in an environmental chamber 
(Plas-Labs) maintained at 37° C. and perfused With either a 
gas mixture of 85% nitrogen, 10% hydrogen and 5% carbon 
dioxide to induce anoxic conditions, or a mixture of air and 
5% carbon dioxide to induce normoxic conditions. After 
four hours, plates Were removed from the chambers and 
medium Was changed to groWth medium With compound-D 
SEQ ID NO:1 at appropriate concentrations. Cells Were 
returned to the air-5% CO2 incubator until the next day. 
Alamar Blue (AccuMed International Companies), con 
taining a ?uorometric/colorimetric oxidation/reduction 
indicator, Was added to the assay medium in an amount 
equal to 10% of the assay volume. Cells Were returned to the 
incubator for tWo to four hours. Fluorescence of each Well 
Was measured at an excitation Wavelength of 530 nm and an 
emission Wavelength of 580 nm in a CytoFluor Multi-Well 
Plate Reader (PerSeptive Biosystems). The average ?uores 
cence readings from three Wells Were used as a relative 
measurement of the metabolic activity of the cells. 
Viability Was assessed in the same Wells using a crystal 
violet staining technique. Cells Were Washed tWice With 
phosphate buffered saline (PBS). Cells Were lysed and 
stained With 0.5% crystal violet in 20% methanol. Fifty 
microliters of this solution Was left in the Wells for ?ve 
minutes. The plates Were then Washed under sloW running 
Water about ?ve times or until the Water ran clear. Excess 
Water Was removed by inverting and tapping the plates on an 
absorbent surface. Stained cells Were solubliZed With at least 
200 pal/Well of a solution of 0.1% sodium citrate in 50% 
ethanol. After ten minutes, 50 pl of solubliZed stain Was 
transferred to a 96-Well microtiter plate and read at an 
absorbance of 570 nm and subtracted from reference Wave 
length of 650 nm. The average readings from three Wells 
Were used as a relative measurement of the viability of the 
cells. 
As shoWn in FIG. 10, cell metabolic activity as assessed 
by Alamar Blue uptake by PC12 cells Was increased With 
increasing concentrations of compound-D SEQ ID NO:1. 
As shoWn in FIG. 11, cell viability as assessed by crystal 
violet uptake of PC12 cells Was increased With increasing 
concentrations of compound-D SEQ ID NO:1. 
As shoWn in FIG. 12, NGF differentiated cells under 
ischemic conditions and treated With increasing concentra 
tions of compound-D SEQ ID NO:1 (bottom line) shoWed 
increasing viability, With the highest concentration of 
compound-D SEQ ID NO:1 shoWing cell viability slightly 
exceeding the positive control. Also as shoWn in FIG. 12, 
NGF differentiated cells under suboptimal metabolic condi 
tions and treated With increasing concentrations of 
compound-D SEQ ID NO:1 (top line) shoWed increasing 
cell viability. 
Oxidative damage has been suggested to play a critical 
role in a number of cardiovascular diseases including 
atherosclerosis, fetal arrhythmia, aortic stenosis, cardiac 
hypertrophy, or in valvular diseases Where prolonged car 
diac ischemia is a factor. During reperfusion, reactive oxy 
gen species including hydrogen peroxide (HZOZ) and 
hydroxyl radicals are found in the myocardium. These 
oxidants can be derived from various sources such as 
activated neutrophils, xanthine oxidase, mitochondrial 
respiration, and arachidonic acid metabolism. The resulting 
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oxidative damage has been shoWn to cause cell death in 
many experimental systems. (Chen, Q. M., Bahl, J. 1., 
Archives of Biochemistry and Biophysics, Vol. 373, No. 1, 
242—248, Jan. 1, 2000). 
The rat myoblast cell line H9C2 Was used to measure 
myocardial cell necrosis. H9C2 cells Were plated onto 96 
Well plates and groWn to con?uency in DMEM +10% FBS. 
Plates Were Washed one time With assay buffer consisting of 
phenol red free DMEM +2.5% FBS supplemented With 
nonessential amino acids, sodium pyruvate and HEPES 
buffer. All test reagents Were made using the assay buffer. 
Compound-D SEQ ID NO:1 Was diluted in assay buffer to 
2><?nal concentrations, ranging from 20 nM to 0.2 nM. H2O2 
stock (30%) Was diluted to 2><?nal concentration (0.2 mM) 
in assay buffer. 
Immediately folloWing the Wash step, 50 pl 
2><compound-D SEQ ID NO:1 at varying concentrations or 
assay buffer only (control) Was added to quadruplicate Wells 
of a 96 Well plate. Cells Were incubated at 37° C. under 5% 
CO2 for thirty minutes. 
FolloWing the pre-incubation, 50 pl of 2><(0.2 mM) H2O2 
Was added to all Wells except the controls (media only, no 
treatment). The ?nal H2O2 concentration Was 0.1 mM. The 
plate Was again incubated at 37° C. for four hours. 
The cell supernatants Were immediately assayed for lac 
tate dehydrogenase (LDH) release using the CytoTox 96 
Non-Radioactive Cytotoxicity Assay (Promega, catalogue 
#G 1780), folloWing the manufacturer’s assay procedures. 
LDH is a stable cytosolic enZyme that is released upon cell 
lysis. It is used to measure either cell mediated cytoxicity or 
cytotoxicity mediated by chemicals or other agents, and 
provides a sensitive marker of cell damage and necrosis. 
Brie?y, 50 pl supernatant samples from each Well Were 
transferred to another 96 Well plate. Assay media only and 
total cell lysates Were included as controls. Substrate mix 
(50 pl ) Was added to all Wells and the plate Was covered and 
incubated in the dark for thirty minutes at room temperature. 
Stop solution (50 pl) Was added to each Well and the 
absorbance at 490 nM Was recorded. Assay media only 
absorbance values Were subtracted to correct for any LDH 
activity that may be present in the assay buffer. 
As shoWn in FIG. 13, cell necrosis due to oxidative 
damage Was decreased in the presence of compound-D SEQ 
ID NO:1. 
In summary, a compound that is administered to a mam 
mal to reduce the injury associated With ischemia and 
reperfusion of organs such as the heart is disclosed. The 
compound is Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile 
Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 SEQ ID NO:1. Admin 
istration prior to an ischemic event reduces tissue necrosis 
and preserves organ function, as measured by standard 
physiological indices of organ function. The compound may 
be administered in a time frame from 24 h up to 15 min prior 
to planned ischemia, or even during an ischemic period. 
It should be understood that the embodiments of the 
present invention shoWn and described in the speci?cation 
are only preferred embodiments of the inventors Who are 
skilled in the art and thus are not limiting in any Way. For 
example, compound-D SEQ ID NO:1 may be used as a 
protective agent for organs other than the heart. Organs 
isolated for transplant such as kidney, liver, lung, cornea, etc. 
may have enhanced viability after exposure to compound-D 
SEQ ID NO:1. Similarly, compound-D SEQ ID NO:1 may 
be administered to individuals in Which ischemia to organs 
other than the heart has occurred or Will occur. Therefore 
various changes, modi?cations or alterations to these 
embodiments may be made or resorted to Without departing 
from the spirit of the invention and the scope of the 
folloWing claims. 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOs: 1 
<210> SEQ ID NO 1 
<2ll> LENGTH: 17 
<2 12> TYPE: PRT 
<213> ORGANISM: XYZ 
<220> FEATURE: 
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (0) . . . (0) 
<221> NAME/KEY: MODIREs 
<222> LOCATION: ( 1) . . . (0) 
<223> OTHER INFORMATION: Xaa = D-Leu 
<400> SEQUENCE: 1 
Tyr Xaa Phe Ala Asp Val Ala Ser Thr Ile Gly Asp Phe Phe His Ser 
1 5 l0 
Ile 
15 
What is claimed is: 
1. A method of protecting against ischemia and reperfu 
sion injury in a human comprising administering an effective 
amount of compound-D (SEQ ID NO:1) to the human in a 
pharmaceutically acceptable formulation. 
2. The method of claim 1 Wherein administration is prior 
to onset of ischemia. 
3. The method of claim 2 Wherein administration is about 
24 hours prior to onset of ischemia. 
4. The method of claim 1 Wherein compound-D SEQ ID 
NO:1 is administered as a solution. 
5. The method of claim 1 Wherein compound-D SEQ ID 
NO:1 is administered parenterally. 
6. The method of claim 1 Wherein compound-D (SEQ ID 
NO:1) is administered at an amount of about 2 mg/kg of 
body Weight of the human. 
25 
35 
7. The method of claim 1 Wherein compound-D SEQ ID 
NO:1 is administered to protect against myocardial 
ischemia. 
8. The method of claim 1 Wherein the formulation further 
includes arginine hydrochloride. 
9. A method for reducing effects of ischemia in a human 
comprising administering an effective amount of 
compound-D (SEQ ID NO:1) in a pharmaceutically accept 
able carrier to the human. 
10. The method of claim 19 Wherein compound-D SEQ 
ID NO:1 is administered prior to ischemia. 
11. The method of claim 9 Wherein compound-D (SEQ ID 
NO:1) is administered concurrently With onset of ischemia. 
12. The method of claim 9 Wherein compound-D (SEQ ID 
NO:1) is administered at least one hour after onset of 
ischemia. 
PATENT NO. 
DATED 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
: 6,645,938 B2 
: November 11, 2003 
Page 1 of 2 
INVENTOR(S) : Oeltgen et al. 
It is certified that error appears in the above-identi?ed patent and that said Letters Patent is 
hereby corrected as shown below: 
Title page, 
Item [56], References Cited, OTHER PUBLICATIONS, reference “Bolling et al.,” 
“Delta opioid agonist/antagonist activity and ischemia tolerance,” should be -- Delta 
opioid agonist/antagonist activity and ischemic tolerance, - 
“Schultz et al.,” “Morphone mimics the cardioprotective effect...” should be - 
Morphine mimics the cardioprotective effect.. - 
Two references are omitted -- Bolling et al., “Use of “natural” hibernation induction 
triggers for myocardial protection”, annals Thorac. Surg.:623-627, 1997 and Bolling et 
al., “Hibernation triggers and myocardial protection”, Circulation 98:11220-11223, 
1998 - 
Column 4 
Line 42, “FIGS. 2 and 3,respetively” should be -- FIGS. 2 and 3, respectively for high 
?avor - 
Column 5 
Line 65, “SEQ ID NO:1,it Was...” should be -- SEQ ID NO:1, it Was - 
Lil'l? 67, “(KATP)” Should b6 -- (KATP) - 
Column 6 
Line 51, “pO2,pCO2,pH and...” should be -- p02, pCO2, pH and... - 
Line 59, “P012” should be -- PC12 - 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO. : 6,645,938 B2 Page 2 of 2 
DATED : November 11, 2003 
INVENTOR(S) : Oeltgen et al. 
It is certified that error appears in the above-identi?ed patent and that said Letters Patent is 
hereby corrected as shown below: 
Column 9 
Line 20, in the Sequence Listing, “He,” should be -- IIe NH; - 
Lines 32 and 34, “compound-D SEQ ID NO:1. . .” should be -- compound-D 
(SEQ ID NO:1)... - 
Column 10 
Line 24, “compound-D SEQ ID NO:1. . .” should be -- compound-D 
(SEQ ID NO:1)... - 
Line 32, “The method of claim 19 wherein...” should be -- The method of claim 9 
wherein... - 
Signed and Sealed this 
Sixth Day of July, 2004 
“Vt/ADJ” 
JON W. DUDAS 
Acting Director ofthe United States Patent and Trademark O?‘ice 
